JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
about
Severe combined immunodeficiences: new and old scenarios.CD22 Exon 12 deletion is a characteristic genetic defect of therapy-refractory clones in paediatric acute lymphoblastic leukaemia.Inducing apoptosis in chemotherapy-resistant B-lineage acute lymphoblastic leukaemia cells by targeting HSPA5, a master regulator of the anti-apoptotic unfolded protein response signalling network.
P2860
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
@en
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
@nl
type
label
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
@en
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
@nl
prefLabel
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
@en
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
@nl
P2860
P356
P1476
JAK3 pathway is constitutively active in B-lineage acute lymphoblastic leukemia.
@en
P2093
Jason Pitt
Sanjive Qazi
P2860
P356
10.1586/ERA.10.203
P577
2010-11-11T00:00:00Z